CTKB - Cytek Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.13
DETAILS
HIGH:
$5.50
LOW:
$4.75
MEDIAN:
$5.12
CONSENSUS:
$5.13
UPSIDE:
27.93%
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Revenue | 201.5 | 200.5 | 193.0 | 164.0 | 128.0 | 92.8 | 57.9 |
| Cost of Revenue | 97.0 | 89.3 | 83.6 | 63.1 | 48.8 | 41.1 | 29.2 |
| Gross Profit | 104.5 | 111.1 | 109.4 | 101.0 | 79.1 | 51.7 | 28.7 |
| Operating Expenses | |||||||
| R&D Expenses | 36.5 | 39.4 | 44.2 | 34.9 | 24.4 | 13.7 | 8.9 |
| SG&A Expenses | 108.4 | 92.2 | 93.1 | 67.9 | 45.5 | 24.4 | 17.0 |
| Other Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 20.0 |
| Operating Expenses | 144.8 | 131.6 | 137.3 | 102.8 | 70.0 | 38.1 | 45.9 |
| Operating Income | |||||||
| Operating Income | (40.4) | (20.5) | (27.8) | (1.8) | 9.2 | 13.7 | (17.3) |
| Interest Expense | 0.5 | 0 | 2.1 | 2.6 | 1.7 | 0.3 | 0.0 |
| Interest Income | 2.2 | 10.4 | 6.4 | 4.6 | 0.0 | 0.1 | 0.7 |
| Profitability | |||||||
| EBITDA | (17.4) | (10.0) | (4.4) | 9.5 | 8.9 | 15.4 | (16.0) |
| EBIT | (29.4) | (20.5) | (13.6) | 3.8 | 7.7 | 14.8 | (16.3) |
| Income Before Tax | (29.8) | (5.7) | (15.7) | 1.3 | 5.9 | 14.4 | (16.3) |
| Income Tax Expense | 36.7 | 0.3 | (3.6) | (1.2) | 2.9 | (5.0) | 0.5 |
| Net Income | (66.5) | (6.0) | (12.1) | 2.6 | 3.0 | 19.4 | (16.8) |
| Per Share Data | |||||||
| EPS (Basic) | -0.52 | -0.05 | -0.09 | 0.02 | 0.03 | 0.02 | -0.13 |
| EPS (Diluted) | -0.52 | -0.05 | -0.09 | 0.02 | 0.03 | 0.02 | -0.13 |
| Shares Outstanding | 127.7 | 130.6 | 135.3 | 134.5 | 133.7 | 133.0 | 133.0 |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Current Assets | |||||||
| Cash & Cash Equivalents | 90.9 | 98.7 | 167.3 | 296.6 | 364.6 | 165.2 | 30.1 |
| Short-Term Investments | 170.7 | 179.1 | 95.1 | 44.5 | 0 | 0 | 0 |
| Net Receivables | 72.1 | 60.6 | 56.1 | 50.9 | 29.6 | 18.1 | 17.7 |
| Inventory | 48.4 | 43.9 | 60.9 | 48.2 | 32.2 | 23.0 | 18.4 |
| Other Current Assets | 3.0 | 2.0 | 2.6 | 6.7 | 0.7 | 1.3 | 0.4 |
| Total Current Assets | 392.0 | 396.4 | 392.1 | 454.0 | 431.7 | 208.6 | 67.8 |
| Non-Current Assets | |||||||
| Property, Plant & Equipment | 29.3 | 28.1 | 29.3 | 27.6 | 5.9 | 2.1 | 1.0 |
| Goodwill | 16.7 | 16.7 | 16.2 | 10.1 | 10.1 | 0.5 | 0.5 |
| Intangible Assets | 16.8 | 20.1 | 23.1 | 4.3 | 4.7 | 0.3 | 0.3 |
| Long-Term Investments | 0 | 1.6 | 1.6 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 6.7 | 3.2 | 1.8 | 3.0 | 1.7 | 1.1 | 0.8 |
| Total Non-Current Assets | 69.5 | 103.1 | 102.4 | 65.5 | 31.6 | 11.4 | 2.6 |
| Total Assets | 461.5 | 499.5 | 494.5 | 519.5 | 463.3 | 220.0 | 70.4 |
| Current Liabilities | |||||||
| Account Payables | 6.4 | 5.5 | 3.0 | 4.8 | 3.0 | 2.9 | 2.3 |
| Short-Term Debt | 6.3 | 4.7 | 0.6 | 0.6 | 0 | 2.8 | 0 |
| Deferred Revenue | 29.6 | 26.6 | 22.7 | 14.5 | 8.1 | 4.3 | 3.5 |
| Other Current Liabilities | 18.1 | 1.9 | 21.2 | 17.3 | 12.0 | 12.0 | 10.5 |
| Total Current Liabilities | 77.8 | 67.7 | 56.2 | 49.0 | 33.2 | 26.5 | 21.0 |
| Non-Current Liabilities | |||||||
| Long-Term Debt | 0.5 | 1.1 | 1.6 | 2.3 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 9.1 | 11.4 | 18.9 | 17.2 | 14.9 | 206.0 | 89.2 |
| Total Non-Current Liabilities | 42.0 | 36.1 | 45.2 | 44.9 | 24.7 | 209.5 | 91.0 |
| Total Liabilities | 119.8 | 103.8 | 101.4 | 93.9 | 57.9 | 236.0 | 112.1 |
| Stockholders' Equity | |||||||
| Common Stock | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| Retained Earnings | (101.7) | (35.2) | (29.2) | (17.0) | (19.6) | (22.6) | (42.0) |
| Accumulated Other Comprehensive Income | 2.2 | 0.0 | (1.3) | (0.7) | 0.9 | 0.1 | (0.1) |
| Total Stockholders' Equity | 341.7 | 395.7 | 393.1 | 425.3 | 405.0 | (16.0) | (41.7) |
| Total Liabilities & Equity | 461.5 | 499.5 | 494.5 | 519.5 | 463.3 | 220.0 | 70.4 |
| Debt Metrics | |||||||
| Total Debt | 23.7 | 17.0 | 14.1 | 18.1 | 0 | 2.8 | 0 |
| Net Debt | (67.1) | (81.7) | (153.2) | (278.5) | (364.6) | (162.5) | (30.1) |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||
| Net Income | (66.5) | (6.0) | (12.1) | 2.5 | 3.0 | 19.4 | (16.8) |
| Depreciation & Amortization | 12.0 | 10.5 | 9.2 | 5.7 | 1.2 | 0.6 | 0.3 |
| Stock-Based Compensation | 24.6 | 26.8 | 22.0 | 16.6 | 6.6 | 0.6 | 0.3 |
| Change in Working Capital | (4.8) | 7.7 | (10.5) | (39.9) | (8.6) | (7.5) | 1.2 |
| Other Non-Cash Items | (3.5) | (10.8) | (3.3) | 3.0 | 2.4 | 2.1 | 1.3 |
| Operating Cash Flow | (4.7) | 25.4 | 5.3 | (12.2) | 4.6 | 15.2 | (13.7) |
| Investing Activities | |||||||
| Capital Expenditure | (4.1) | (3.5) | (4.8) | (9.9) | (4.4) | (1.5) | (1.0) |
| Acquisitions | 0.3 | (0.5) | (45.1) | 0 | (16.6) | 0 | 0 |
| Purchases of Investments | (278.2) | (274.1) | (175.9) | (46.0) | 0 | 0 | 0 |
| Sales/Maturities of Investments | 292.2 | 195 | 132 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (0.1) | 0.1 | (0.2) | (0.1) | 0 | 0 | 0 |
| Investing Cash Flow | 10.1 | (83.0) | (93.9) | (55.9) | (21.0) | (1.5) | (1.0) |
| Financing Activities | |||||||
| Net Debt Issuance | 0.8 | 3.6 | (0.6) | 2.9 | (2.8) | 2.8 | 0 |
| Stock Repurchased | (15.1) | (21.6) | (44.2) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (0.7) | 2.2 | 2.9 | 2.6 | 0.6 | 0.2 | 0.1 |
| Financing Cash Flow | (13.4) | (15.8) | (41.8) | 5.5 | 213.6 | 122.6 | 0.1 |
| Cash Position | |||||||
| Net Change in Cash | (7.9) | (68.9) | (131.9) | (65.1) | 198.5 | 135.6 | (14.7) |
| Cash at Beginning | 98.7 | 167.6 | 299.5 | 364.6 | 166.1 | 30.5 | 45.1 |
| Cash at End | 90.9 | 98.7 | 167.6 | 299.5 | 364.6 | 166.1 | 30.5 |
| Free Cash Flow | (8.8) | 21.9 | 0.5 | (22.1) | 0.3 | 13.6 | (14.7) |
| Key Metrics | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 201.5 | 200.5 | 193.0 | 164.0 | 128.0 | 92.8 | 57.9 |
| Gross Profit | 104.5 | 111.1 | 109.4 | 101.0 | 79.1 | 51.7 | 28.7 |
| Operating Income | (40.4) | (20.5) | (27.8) | (1.8) | 9.2 | 13.7 | (17.3) |
| Net Income | (66.5) | (6.0) | (12.1) | 2.6 | 3.0 | 19.4 | (16.8) |
| EPS (Diluted) | -0.52 | -0.05 | -0.09 | 0.02 | 0.03 | 0.02 | -0.13 |
| Balance Sheet | |||||||
| Cash & Equivalents | 90.9 | 98.7 | 167.3 | 296.6 | 364.6 | 165.2 | 30.1 |
| Total Assets | 461.5 | 499.5 | 494.5 | 519.5 | 463.3 | 220.0 | 70.4 |
| Total Debt | 23.7 | 17.0 | 14.1 | 18.1 | 0 | 2.8 | 0 |
| Stockholders' Equity | 341.7 | 395.7 | 393.1 | 425.3 | 405.0 | (16.0) | (41.7) |
| Cash Flow | |||||||
| Operating Cash Flow | (4.7) | 25.4 | 5.3 | (12.2) | 4.6 | 15.2 | (13.7) |
| Capital Expenditure | (4.1) | (3.5) | (4.8) | (9.9) | (4.4) | (1.5) | (1.0) |
| Free Cash Flow | (8.8) | 21.9 | 0.5 | (22.1) | 0.3 | 13.6 | (14.7) |